FI104408B - Förfarande för framställning av tvåfasiska avgivningsformulationer för lipofiliska läkemedel - Google Patents

Förfarande för framställning av tvåfasiska avgivningsformulationer för lipofiliska läkemedel Download PDF

Info

Publication number: FI104408B
Authority: FI; Finland
Prior art keywords: sustained release; pharmaceutically active; fatty acid; att; förfarande enligt
Prior art date: 1990-10-19

Application number

FI931745A

Other languages

English (en)

Finnish (fi)

Other versions

FI931745L (fi

FI931745A0 (fi

Inventor

Stephen George Barnwell

Original Assignee

Cortecs Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-10-19

Filing date

1993-04-16

Publication date

2000-01-31

1993-04-16 Application filed by Cortecs Ltd filed Critical Cortecs Ltd

1993-04-16 Publication of FI931745L publication Critical patent/FI931745L/fi

1993-04-16 Publication of FI931745A0 publication Critical patent/FI931745A0/fi

2000-01-31 Application granted granted Critical

2000-01-31 Publication of FI104408B publication Critical patent/FI104408B/sv

Links

239000000203 mixture Substances 0.000 title claims abstract description 65
238000009472 formulation Methods 0.000 title claims abstract description 58
239000003814 drug Substances 0.000 title claims description 61
229940079593 drug Drugs 0.000 title claims description 60
238000000034 method Methods 0.000 title claims description 25
230000008569 process Effects 0.000 title claims description 13
238000002360 preparation method Methods 0.000 title claims description 10
230000002051 biphasic effect Effects 0.000 title description 4
238000013268 sustained release Methods 0.000 claims abstract description 43
239000012730 sustained-release form Substances 0.000 claims abstract description 43
235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 42
239000000194 fatty acid Substances 0.000 claims abstract description 41
229930195729 fatty acid Natural products 0.000 claims abstract description 41
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims abstract description 40
239000013543 active substance Substances 0.000 claims abstract description 39
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 23
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 23
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 23
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 23
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 23
229960003712 propranolol Drugs 0.000 claims abstract description 19
239000002327 cardiovascular agent Substances 0.000 claims abstract description 9
229940125692 cardiovascular agent Drugs 0.000 claims abstract description 9
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 8
229960001597 nifedipine Drugs 0.000 claims abstract description 8
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims abstract description 5
SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 claims abstract description 5
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims abstract description 5
229960004166 diltiazem Drugs 0.000 claims abstract description 5
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims abstract description 5
229960002237 metoprolol Drugs 0.000 claims abstract description 5
229960001722 verapamil Drugs 0.000 claims abstract description 5
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims abstract description 3
235000020778 linoleic acid Nutrition 0.000 claims abstract description 3
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims abstract description 3
ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims abstract 2
229960001783 nicardipine Drugs 0.000 claims abstract 2
150000004665 fatty acids Chemical class 0.000 claims description 28
239000005642 Oleic acid Substances 0.000 claims description 22
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 21
239000004480 active ingredient Substances 0.000 claims description 11
239000000463 material Substances 0.000 claims description 10
239000004094 surface-active agent Substances 0.000 claims description 10
-1 C24 fatty acid Chemical class 0.000 claims description 9
239000003963 antioxidant agent Substances 0.000 claims description 5
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
229920000053 polysorbate 80 Polymers 0.000 claims description 3
229940068968 polysorbate 80 Drugs 0.000 claims description 3
230000003078 antioxidant effect Effects 0.000 claims 2
KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 claims 1
208000024172 Cardiovascular disease Diseases 0.000 claims 1
230000003213 activating effect Effects 0.000 claims 1
238000013265 extended release Methods 0.000 claims 1
230000035772 mutation Effects 0.000 claims 1
230000000069 prophylactic effect Effects 0.000 claims 1
238000011321 prophylaxis Methods 0.000 claims 1
239000007921 spray Substances 0.000 claims 1
229920001169 thermoplastic Polymers 0.000 claims 1
239000012815 thermoplastic material Substances 0.000 claims 1
239000004416 thermosoftening plastic Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 13
230000002440 hepatic effect Effects 0.000 abstract description 10
238000010521 absorption reaction Methods 0.000 abstract description 9
210000004324 lymphatic system Anatomy 0.000 abstract description 7
238000007911 parenteral administration Methods 0.000 abstract description 6
231100000673 dose–response relationship Toxicity 0.000 abstract description 4
229920006395 saturated elastomer Polymers 0.000 abstract description 4
230000010224 hepatic metabolism Effects 0.000 abstract description 3
239000000126 substance Substances 0.000 abstract description 3
230000001225 therapeutic effect Effects 0.000 abstract description 3
230000036770 blood supply Effects 0.000 abstract 1
150000002888 oleic acid derivatives Chemical class 0.000 abstract 1
210000004185 liver Anatomy 0.000 description 21
150000001875 compounds Chemical class 0.000 description 16
230000000694 effects Effects 0.000 description 13
230000004060 metabolic process Effects 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
239000002775 capsule Substances 0.000 description 11
238000010579 first pass effect Methods 0.000 description 11
239000000499 gel Substances 0.000 description 11
210000001035 gastrointestinal tract Anatomy 0.000 description 9
239000002253 acid Substances 0.000 description 8
239000002585 base Substances 0.000 description 8
210000002751 lymph Anatomy 0.000 description 8
239000006185 dispersion Substances 0.000 description 7
238000012360 testing method Methods 0.000 description 7
108090001030 Lipoproteins Proteins 0.000 description 6
102000004895 Lipoproteins Human genes 0.000 description 6
239000002876 beta blocker Substances 0.000 description 6
229940097320 beta blocking agent Drugs 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
230000001839 systemic circulation Effects 0.000 description 6
108010004103 Chylomicrons Proteins 0.000 description 5
239000002702 enteric coating Substances 0.000 description 5
238000009505 enteric coating Methods 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
239000007903 gelatin capsule Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
230000028327 secretion Effects 0.000 description 5
238000003756 stirring Methods 0.000 description 5
230000009974 thixotropic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
229910002012 Aerosil® Inorganic materials 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
230000002411 adverse Effects 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
150000002632 lipids Chemical class 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
229960000984 tocofersolan Drugs 0.000 description 4
230000007704 transition Effects 0.000 description 4
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 3
229910002016 Aerosil® 200 Inorganic materials 0.000 description 3
229940127291 Calcium channel antagonist Drugs 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
150000001408 amides Chemical class 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000012738 dissolution medium Substances 0.000 description 3
239000013583 drug formulation Substances 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
210000001842 enterocyte Anatomy 0.000 description 3
125000005456 glyceride group Chemical group 0.000 description 3
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 3
230000001926 lymphatic effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000037353 metabolic pathway Effects 0.000 description 3
229960004570 oxprenolol Drugs 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000002076 α-tocopherol Substances 0.000 description 3
235000004835 α-tocopherol Nutrition 0.000 description 3
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
239000004322 Butylated hydroxytoluene Substances 0.000 description 2
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
102100028675 DNA polymerase subunit gamma-2, mitochondrial Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
108010010234 HDL Lipoproteins Proteins 0.000 description 2
102000015779 HDL Lipoproteins Human genes 0.000 description 2
101000837415 Homo sapiens DNA polymerase subunit gamma-2, mitochondrial Proteins 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
108010007622 LDL Lipoproteins Proteins 0.000 description 2
102000007330 LDL Lipoproteins Human genes 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
108010062497 VLDL Lipoproteins Proteins 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
229940095259 butylated hydroxytoluene Drugs 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
238000000605 extraction Methods 0.000 description 2
235000021323 fish oil Nutrition 0.000 description 2
239000012458 free base Substances 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
150000004668 long chain fatty acids Chemical class 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
210000003240 portal vein Anatomy 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000005086 pumping Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
229960004605 timolol Drugs 0.000 description 2
230000032258 transport Effects 0.000 description 2
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
101150102415 Apob gene Proteins 0.000 description 1
101710095342 Apolipoprotein B Proteins 0.000 description 1
102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
101100248253 Arabidopsis thaliana RH40 gene Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
239000011627 DL-alpha-tocopherol Substances 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
108010051696 Growth Hormone Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
239000004902 Softening Agent Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
230000003373 anti-fouling effect Effects 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
229940114079 arachidonic acid Drugs 0.000 description 1
235000021342 arachidonic acid Nutrition 0.000 description 1
239000000823 artificial membrane Substances 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
229940124748 beta 2 agonist Drugs 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
ITKVLPYNJQOCPW-UHFFFAOYSA-N chloro-(chloromethyl)-dimethylsilane Chemical compound C[Si](C)(Cl)CCl ITKVLPYNJQOCPW-UHFFFAOYSA-N 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000007931 coated granule Substances 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
230000010339 dilation Effects 0.000 description 1
238000007922 dissolution test Methods 0.000 description 1
229960003638 dopamine Drugs 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960003580 felodipine Drugs 0.000 description 1
229960001022 fenoterol Drugs 0.000 description 1
LSLYOANBFKQKPT-UHFFFAOYSA-N fenoterol Chemical compound C=1C(O)=CC(O)=CC=1C(O)CNC(C)CC1=CC=C(O)C=C1 LSLYOANBFKQKPT-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
230000009969 flowable effect Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
230000000762 glandular Effects 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000010240 hepatic drug metabolism Effects 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000002555 ionophore Substances 0.000 description 1
230000000236 ionophoric effect Effects 0.000 description 1
229960001632 labetalol Drugs 0.000 description 1
238000002386 leaching Methods 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
239000006210 lotion Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
230000004118 muscle contraction Effects 0.000 description 1
VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
229960004255 nadolol Drugs 0.000 description 1
229960005425 nitrendipine Drugs 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
235000020660 omega-3 fatty acid Nutrition 0.000 description 1
229940012843 omega-3 fatty acid Drugs 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
229940096717 pamine Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940101027 polysorbate 40 Drugs 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000008213 purified water Substances 0.000 description 1
230000019081 regulation of lipoprotein metabolic process Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
IYMMESGOJVNCKV-SKDRFNHKSA-N rimiterol Chemical compound C([C@@H]1[C@@H](O)C=2C=C(O)C(O)=CC=2)CCCN1 IYMMESGOJVNCKV-SKDRFNHKSA-N 0.000 description 1
229960001457 rimiterol Drugs 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
229960001634 ritodrine Drugs 0.000 description 1
239000005060 rubber Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
238000007789 sealing Methods 0.000 description 1
150000003335 secondary amines Chemical group 0.000 description 1
210000002955 secretory cell Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
238000007711 solidification Methods 0.000 description 1
230000008023 solidification Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
229960000195 terbutaline Drugs 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
235000021122 unsaturated fatty acids Nutrition 0.000 description 1
150000004670 unsaturated fatty acids Chemical class 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Oil, Petroleum & Natural Gas (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
Professional, Industrial, Or Sporting Protective Garments (AREA)
Laminated Bodies (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Materials For Medical Uses (AREA)

FI931745A 1990-10-19 1993-04-16 Förfarande för framställning av tvåfasiska avgivningsformulationer för lipofiliska läkemedel FI104408B (sv)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB9022788		1990-10-19
GB909022788A GB9022788D0 (en)	1990-10-19	1990-10-19	Pharmaceutical formulations
GB9101824		1991-01-28
PCT/GB1991/001824 WO1992006680A1 (en)	1990-10-19	1991-10-18	Biphasic release formulations for lipophilic drugs

Publications (3)

Publication Number	Publication Date
FI931745L FI931745L (fi)	1993-04-16
FI931745A0 FI931745A0 (fi)	1993-04-16
FI104408B true FI104408B (sv)	2000-01-31

Family

ID=10684032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI931745A FI104408B (sv)	1990-10-19	1993-04-16	Förfarande för framställning av tvåfasiska avgivningsformulationer för lipofiliska läkemedel

Country Status (21)

Country	Link
US (1)	US5391377A (sv)
EP (1)	EP0553178B1 (sv)
JP (1)	JP3276368B2 (sv)
KR (1)	KR100188642B1 (sv)
AT (1)	ATE122881T1 (sv)
AU (1)	AU656924B2 (sv)
BG (1)	BG61383B1 (sv)
CA (1)	CA2093206C (sv)
CZ (1)	CZ282822B6 (sv)
DE (1)	DE69110052T2 (sv)
DK (1)	DK0553178T3 (sv)
ES (1)	ES2073177T3 (sv)
FI (1)	FI104408B (sv)
GB (1)	GB9022788D0 (sv)
HK (1)	HK85296A (sv)
HU (2)	HUT64215A (sv)
NO (1)	NO305505B1 (sv)
RO (1)	RO114739B1 (sv)
RU (1)	RU2121344C1 (sv)
SK (1)	SK279845B6 (sv)
WO (1)	WO1992006680A1 (sv)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5662933A (en) *	1993-09-09	1997-09-02	Edward Mendell Co., Inc.	Controlled release formulation (albuterol)
US5773025A (en)	1993-09-09	1998-06-30	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems--amorphous drugs
US5455046A (en) *	1993-09-09	1995-10-03	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems for insoluble drugs
GB9325445D0 (en) *	1993-12-13	1994-02-16	Cortecs Ltd	Pharmaceutical formulations
US5567592A (en) *	1994-02-02	1996-10-22	Regents Of The University Of California	Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) *	1994-03-16	1994-04-27	Scherer Ltd R P	Delivery systems for hydrophobic drugs
US5430021A (en) *	1994-03-18	1995-07-04	Pharmavene, Inc.	Hydrophobic drug delivery systems
DE4443175A1 (de) *	1994-12-05	1996-06-13	Jenapharm Gmbh	Neue pulsatile Arzneiform
US5834024A (en)	1995-01-05	1998-11-10	Fh Faulding & Co. Limited	Controlled absorption diltiazem pharmaceutical formulation
EP0808154B1 (en) *	1995-02-06	2000-12-20	Elan Pharma International Limited	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5665386A (en) *	1995-06-07	1997-09-09	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2224227A1 (en) *	1995-06-07	1996-12-19	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) *	1995-06-07	1998-02-10	Avmax, Inc.	Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6024980A (en) *	1996-06-28	2000-02-15	Mcneil-Ppc, Inc.	Multiphase soft gelatin dosage form
MX9801835A (es)	1996-07-08	1998-08-30	Mendell Co Inc Edward	Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
US6949264B1 (en)	1996-11-27	2005-09-27	Wm. Wrigley Jr. Company	Nutraceuticals or nutritional supplements and method of making
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
IN186245B (sv)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
US6056977A (en)	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
US20030008919A1 (en) *	1999-06-03	2003-01-09	Jean-Baptiste Roullet	Use of retinoids to treat high blood pressure and other cardiovascular disease
JP2002500190A (ja)	1998-01-08	2002-01-08	ザリージェンツオブザユニバーシティオブカリフォルニア	海洋海綿から誘導されるキネシンモーターモジュレーター
US7030155B2 (en) *	1998-06-05	2006-04-18	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US6524620B2 (en)	1998-07-20	2003-02-25	Andrx Pharmaceuticals, Inc.	Diltiazem controlled release formulation and method of manufacture
US6200968B1 (en) *	1998-08-06	2001-03-13	Cephalon, Inc.	Particle-forming compositions containing fused pyrrolocarbazoles
FR2782006B1 (fr) *	1998-08-07	2002-04-19	Gattefosse Ets Sa	Composition a liberation prolongee apte a former une micro-emulsion
US6638522B1 (en)	1998-12-11	2003-10-28	Pharmasolutions, Inc.	Microemulsion concentrate composition of cyclosporin
US7163705B2 (en)	1998-12-15	2007-01-16	Wm. Wrigley Jr. Company	Coated chewing gum product and method of making
US6057289A (en) *	1999-04-30	2000-05-02	Pharmasolutions, Inc.	Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
WO2001087284A2 (en) *	2000-05-11	2001-11-22	Pharmacia Corporation	Aldosterone antagonist composition for release during aldosterone acrophase
US7115288B2 (en)	2000-06-09	2006-10-03	Wm. Wrigley Jr. Company	Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US6664230B1 (en)	2000-08-24	2003-12-16	The Regents Of The University Of California	Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) *	2000-08-24	2013-10-29	Gattadahalli M. Anantharamaiah	Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1492511B3 (fr) *	2002-04-09	2012-05-02	Flamel Technologies	Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7670612B2 (en)	2002-04-10	2010-03-02	Innercap Technologies, Inc.	Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040005359A1 (en) *	2002-06-27	2004-01-08	Cheng Xiu Xiu	Controlled release oral dosage form
US20040077621A1 (en) *	2002-08-08	2004-04-22	Academia Sinica	Antioxidants
RU2217138C1 (ru) *	2002-11-20	2003-11-27	Балавадзе Михаил Элизбарович	Состав "витализин-2" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
EP1594512A4 (en) *	2003-02-11	2007-07-11	Kemia Inc	COMPOUNDS FOR THE TREATMENT OF VIRUS INFECTIONS
US7314640B2 (en) *	2003-07-11	2008-01-01	Mongkol Sriwongjanya	Formulation and process for drug loaded cores
WO2005067897A1 (en) *	2004-01-14	2005-07-28	Lavipharm Laboratories, Inc.	Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
CA2556220A1 (en) *	2004-02-11	2005-08-25	Athpharma Limited	Chronotherapeutic compositions and methods of their use
WO2005108981A1 (en)	2004-05-12	2005-11-17	The Walter And Eliza Hall Institute Of Medical Research	A method of cell isolation
US8648045B2 (en)	2005-03-10	2014-02-11	Ben Gurion University Of The Negev Research And Development Authority Ltd.	VDAC1 compositions and methods of use thereof for regulating apoptosis
EP2371846B1 (en)	2005-03-10	2013-12-04	Ben Gurion University of the Negev Research and Development Authority Ltd.	Voltage dependent anion channel (vdac1) compositions and methods of use thereof for regulating apoptosis
MX2007013430A (es)	2005-04-29	2008-03-19	Univ California	Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
AU2006261599B2 (en)	2005-06-24	2011-10-06	The Walter & Eliza Hall Institute Of Medical Research	Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
US8691272B2 (en) *	2005-12-30	2014-04-08	Intelgenx Corp.	Multilayer tablet
WO2007082352A1 (en)	2006-01-20	2007-07-26	Child Health Research Institute Inc	Method of treatment, prophylaxis and diagnosis of pathologies of the bone
WO2007113837A2 (en) *	2006-04-06	2007-10-11	Ben-Gurion University Of The Negev	N-terminal vdac variants and uses thereof
WO2007123153A1 (ja) *	2006-04-19	2007-11-01	Ono Pharmaceutical Co., Ltd.	経口投与用カプセル
MY153288A (en) *	2006-06-28	2015-01-29	Hovid Berhad	An effective pharmaceutical carrier for poorly bioavailable drugs
WO2008015959A1 (en) *	2006-08-01	2008-02-07	Otsuka Pharmaceutical Co., Ltd.	Pharmaceutical composition improved in absorption of pharmacologically active substance
AU2007309408A1 (en) *	2006-10-27	2008-05-02	Janssen Pharmaceutica N.V.	Dry granulated pharmaceutical compositions and methods for producing same
AU2008279550B2 (en)	2007-06-21	2012-08-09	Angelica Therapeutics, Inc.	Modified toxins
ES2700141T3 (es)	2007-08-02	2019-02-14	Gilead Biologics Inc	Anticuerpos inhibidores LOXL2 y usos de los mismos
WO2009032702A2 (en)	2007-08-28	2009-03-12	Uab Research Foundation	Synthetic apolipoprotein e mimicking polypeptides and methods of use
EP2195331B1 (en) *	2007-08-28	2013-11-20	Uab Research Foundation	Synthetic apolipoprotein e mimicking polypeptides and methods of use
CA2701075C (en) *	2007-10-03	2019-02-12	Wista Laboratories Ltd.	Therapeutic use of diaminophenothiazines.
WO2009110944A1 (en)	2008-02-29	2009-09-11	Angelica Therapeutics, Inc.	Modified toxins
MX2010012318A (es) *	2008-05-12	2010-12-06	Pfizer	Capsula mejorada con ventilaciones.
US20100082438A1 (en) *	2008-10-01	2010-04-01	Ronnie Jack Garmon	Methods and systems for customer performance scoring
US9050276B2 (en)	2009-06-16	2015-06-09	The Trustees Of Columbia University In The City Of New York	Autism-associated biomarkers and uses thereof
US20120244147A1 (en)	2009-08-17	2012-09-27	Theuer Charles P	Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
US8221753B2 (en) *	2009-09-30	2012-07-17	Tracon Pharmaceuticals, Inc.	Endoglin antibodies
ES2363965B1 (es) *	2009-11-20	2013-01-24	Gp Pharm S.A.	Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US20110136815A1 (en) *	2009-12-08	2011-06-09	Horst Zerbe	Solid oral film dosage forms and methods for making same
US10610528B2 (en)	2009-12-08	2020-04-07	Intelgenx Corp.	Solid oral film dosage forms and methods for making same
WO2011088462A2 (en)	2010-01-18	2011-07-21	Albany Medical College	Alpha-fetoprotein 'ring and tail' peptides
EP2608809B1 (en)	2010-08-27	2019-05-22	Gilead Biologics, Inc.	Antibodies to matrix metalloproteinase 9
WO2012051567A2 (en)	2010-10-15	2012-04-19	The Trustees Of Columbia University In The City Of New York	Obesity-related genes and their proteins and uses thereof
US20140213502A1 (en)	2011-04-29	2014-07-31	United States Department of Health and Human Services	Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
EP2760433B1 (en) *	2011-09-29	2023-05-31	PLx Opco Inc.	pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
TW202446781A (zh)	2011-12-28	2024-12-01	日商中外製藥股份有限公司	胜肽化合物之製造方法
HK1204926A1 (en)	2012-02-29	2015-12-11	吉联亚生物科技有限公司	Antibodies to matrix metalloproteinase 9
WO2013130078A1 (en)	2012-02-29	2013-09-06	Gilead Biologics, Inc.	Antibodies to matrix metalloproteinase 9
WO2013128453A1 (en)	2012-03-01	2013-09-06	Yeda Research And Development Co. Ltd.	Regeneration of islet beta cells by hsp60 derived peptides
WO2013139861A1 (en)	2012-03-20	2013-09-26	Luc Montagnier	Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
TW201406707A (zh)	2012-05-04	2014-02-16	Acucela Inc	用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2013293049A1 (en)	2012-07-20	2015-02-26	La Trobe University	Method of diagnosis and treatment
UA115789C2 (uk)	2012-09-05	2017-12-26	Трейкон Фармасутікалз, Інк.	Композиція антитіла до cd105 та її застосування
US20160002315A1 (en)	2013-03-14	2016-01-07	Uab Research Foundation	Apolipoprotein mimetics and uses thereof
JP6549554B2 (ja)	2013-03-15	2019-07-24	ザリージェンツオブザユニバーシティオブカリフォルニア	コレステロール流出を刺激する、減少した毒性を有するペプチド
WO2014152006A2 (en)	2013-03-15	2014-09-25	Intrinsic Lifesciences, Llc	Anti-hepcidin antibodies and uses thereof
EP2968450A4 (en)	2013-03-15	2016-10-26	Angelica Therapeutics Inc	MODIFIED TOXINS
WO2015011711A1 (en)	2013-07-25	2015-01-29	The National Institute for Biotechnology in the Negev Ltd.	Short peptides derived from vdac1, compositions and methods of use thereof
US9873724B2 (en)	2013-12-20	2018-01-23	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Pro-angiogenic peptides and peptide conjugates
EP3110847A1 (en)	2014-02-27	2017-01-04	Gilead Sciences, Inc.	Antibodies to matrix metalloproteinase 9 and methods of use thereof
KR20170018383A (ko)	2014-06-11	2017-02-17	길리애드 사이언시즈, 인코포레이티드	심혈관 질환의 치료 방법
EP3169700A1 (en)	2014-07-17	2017-05-24	Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.	Antagonists of neurokinin b in fish reproduction
US10793614B2 (en)	2014-07-17	2020-10-06	Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd.	Antagonists of fish reproduction
WO2016019333A1 (en)	2014-07-31	2016-02-04	Kinemed, Inc.	The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
WO2016018665A1 (en)	2014-07-31	2016-02-04	Uab Research Foundation	Apoe mimetic peptides and higher potency to clear plasma cholesterol
US10323088B2 (en)	2014-09-22	2019-06-18	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
US9926375B2 (en)	2014-11-12	2018-03-27	Tracon Pharmaceuticals, Inc.	Anti-endoglin antibodies and uses thereof
CA2966905A1 (en)	2014-11-12	2016-05-19	Tracon Pharmaceuticals, Inc.	Anti-endoglin antibodies and uses thereof
BR112018004296B1 (pt)	2015-09-04	2020-05-05	Primatope Therapeutics Inc	anticorpos anti-cd40 humanizados e usos dos mesmos
US10149887B2 (en)	2015-10-23	2018-12-11	Canbas Co., Ltd.	Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6877419B2 (ja)	2015-10-27	2021-05-26	ザユニバーシティーオブクイーンズランド	治療の方法およびそのために有用な剤
WO2017083700A1 (en)	2015-11-13	2017-05-18	The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas	Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
WO2017106566A1 (en)	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
EP3440113A1 (en)	2016-04-08	2019-02-13	Gilead Sciences, Inc.	Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2018071814A1 (en)	2016-10-14	2018-04-19	The Trustees Of Columbia University In The City Of New York	Methods of treating alcohol abuse disorder
JP7173870B2 (ja) *	2016-12-28	2022-11-16	中外製薬株式会社	化合物の膜透過性を改善するための自己乳化型製剤
WO2018137002A1 (en)	2017-01-30	2018-08-02	Hudson Institute of Medical Research	A method of treatment
WO2018213803A1 (en)	2017-05-19	2018-11-22	Neon Therapeutics, Inc.	Immunogenic neoantigen identification
EP3630046B1 (en)	2017-05-30	2024-12-25	The Board of Regents of the University of Oklahoma	Anti-doublecortin-like kinase 1 antibodies and methods of use
SG11202004116QA (en)	2017-11-08	2020-06-29	Biontech Us Inc	T cell manufacturing compositions and methods
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
CA3105448A1 (en)	2018-07-03	2020-01-09	Elstar Therapeutics, Inc.	Anti-tcr antibody molecules and uses thereof
JP2021533777A (ja)	2018-08-16	2021-12-09	ビオンテックユーエスインコーポレイテッド	Ｔ細胞受容体構築物およびその使用
GB2599228B (en)	2019-02-21	2024-02-07	Marengo Therapeutics Inc	Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CN119039441A (zh)	2019-02-21	2024-11-29	马伦戈治疗公司	与nkp30结合的抗体分子及其用途
JP2022536684A (ja)	2019-06-11	2022-08-18	マイエロイド・セラピューティクス，インコーポレーテッド	マクロファージ特異的エンゲージャー組成物およびその使用方法
WO2020252039A1 (en)	2019-06-12	2020-12-17	Biontech Us Inc.	Neoantigen compositions and uses thereof
AU2020416273A1 (en)	2020-01-03	2022-07-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
JP2023518822A (ja)	2020-03-26	2023-05-08	ピーエルエックスオプコインコーポレイテッド	ｐＨ依存的再構築が可能な医薬キャリア、その製造方法及び使用方法
MX2023001815A (es)	2020-08-13	2023-04-11	Biontech Us Inc	Metodos y composiciones de fabricacion de celulas t.
EP4240367A4 (en)	2020-11-04	2024-10-16	Myeloid Therapeutics, Inc.	MODIFIED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
WO2024050138A2 (en)	2022-09-02	2024-03-07	Myeloid Therapeutics, Inc.	Compositions for cell-specific expression and uses thereof
EP4705330A1 (en)	2023-05-05	2026-03-11	The Board of Regents of the University of Oklahoma	Variants of adrenomedullin (am) and adrenomedullin 2/intermedin (am2/imd) and methods of use
WO2025042868A1 (en)	2023-08-23	2025-02-27	The Board Of Regents Of The University Of Oklahoma	Combinations of heteroarotinoids and glycolytic inhibitors for use as cancer treatments
WO2025059113A1 (en)	2023-09-12	2025-03-20	The Board Of Regents Of The University Of Oklahoma	Treatments for enhancing immune response to clostridioides difficile infections
WO2025085360A1 (en)	2023-10-16	2025-04-24	The Board Of Regents Of The University Of Oklahoma	Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects
WO2025169146A1 (en)	2024-02-09	2025-08-14	Kiniksa Pharmaceuticals, Gmbh	Cd40 antagonist or cd154 antagonist for use in mitigating immune responses in protein and gene therapies
WO2025219955A1 (en)	2024-04-17	2025-10-23	BioNTech SE	Soluble tcrs and methods of use thereof
WO2025224684A1 (en)	2024-04-24	2025-10-30	BioNTech SE	Compositions and methods for producing engineered immune cells
WO2025229503A1 (en)	2024-04-29	2025-11-06	BioNTech SE	Methods for identifying exhausted t cells and t-cell receptors thereof
WO2026013643A1 (en)	2024-07-12	2026-01-15	BioNTech SE	Methods and compositions for designing epitope strings with linkers
WO2026047601A1 (en)	2024-08-28	2026-03-05	BioNTech SE	T-cell receptors (tcrs)
WO2026058153A2 (en)	2024-09-10	2026-03-19	BioNTech SE	Hpv-16 t cell receptor uses and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1600639A (en) *	1978-05-23	1981-10-21	Kali Chemie Pharma Gmbh	Medicament preparation having resorption properties and method of producing the same
US4916230A (en) *	1984-07-02	1990-04-10	Merck & Co., Inc.	Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4946870A (en) *	1986-06-06	1990-08-07	Union Carbide Chemicals And Plastics Company Inc.	Delivery systems for pharmaceutical or therapeutic actives
IT1200178B (it) *	1986-07-23	1989-01-05	Alfa Farmaceutici Spa	Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5229422A (en) *	1987-09-07	1993-07-20	Teijin Limited	Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
EP0351897A3 (en) *	1988-06-17	1990-03-21	The Procter & Gamble Company	Skin penetration system for salts of amine-functional drugs
GB8822857D0 (en) *	1988-09-29	1988-11-02	Patralan Ltd	Pharmaceutical formulations
GB8909022D0 (en) *	1989-04-20	1989-06-07	Cortecs Ltd	Pharmaceutical compositions

1990
- 1990-10-19 GB GB909022788A patent/GB9022788D0/en active Pending
1991
- 1991-10-18 CA CA002093206A patent/CA2093206C/en not_active Expired - Fee Related
- 1991-10-18 CZ CZ93641A patent/CZ282822B6/cs not_active IP Right Cessation
- 1991-10-18 HU HU9301121A patent/HUT64215A/hu unknown
- 1991-10-18 RU RU93048157A patent/RU2121344C1/ru active
- 1991-10-18 WO PCT/GB1991/001824 patent/WO1992006680A1/en not_active Ceased
- 1991-10-18 AT AT91918238T patent/ATE122881T1/de not_active IP Right Cessation
- 1991-10-18 RO RO93-00534A patent/RO114739B1/ro unknown
- 1991-10-18 SK SK363-93A patent/SK279845B6/sk unknown
- 1991-10-18 EP EP91918238A patent/EP0553178B1/en not_active Expired - Lifetime
- 1991-10-18 DE DE69110052T patent/DE69110052T2/de not_active Expired - Fee Related
- 1991-10-18 ES ES91918238T patent/ES2073177T3/es not_active Expired - Lifetime
- 1991-10-18 JP JP51690491A patent/JP3276368B2/ja not_active Expired - Fee Related
- 1991-10-18 AU AU87315/91A patent/AU656924B2/en not_active Ceased
- 1991-10-18 US US08/050,064 patent/US5391377A/en not_active Expired - Lifetime
- 1991-10-18 DK DK91918238.6T patent/DK0553178T3/da active
- 1991-10-18 KR KR1019930701127A patent/KR100188642B1/ko not_active Expired - Fee Related
1993
- 1993-04-16 FI FI931745A patent/FI104408B/sv active
- 1993-04-16 NO NO931410A patent/NO305505B1/no not_active IP Right Cessation
- 1993-04-16 BG BG97644A patent/BG61383B1/bg unknown
1995
- 1995-06-30 HU HU95P/P00725P patent/HU211617A9/hu unknown
1996
- 1996-05-16 HK HK85296A patent/HK85296A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR100188642B1 (ko)	1999-06-01
HU9301121D0 (en)	1993-07-28
CZ282822B6 (cs)	1997-10-15
WO1992006680A1 (en)	1992-04-30
ES2073177T3 (es)	1995-08-01
HK85296A (en)	1996-05-24
NO305505B1 (no)	1999-06-14
ATE122881T1 (de)	1995-06-15
NO931410D0 (no)	1993-04-16
NO931410L (no)	1993-04-16
DE69110052T2 (de)	1995-10-05
BG97644A (bg)	1994-04-29
EP0553178B1 (en)	1995-05-24
BG61383B1 (en)	1997-07-31
CA2093206C (en)	2002-01-29
SK279845B6 (sk)	1999-04-13
DE69110052D1 (de)	1995-06-29
FI931745L (fi)	1993-04-16
US5391377A (en)	1995-02-21
AU656924B2 (en)	1995-02-23
RU2121344C1 (ru)	1998-11-10
DK0553178T3 (da)	1995-07-24
FI931745A0 (fi)	1993-04-16
JPH06502143A (ja)	1994-03-10
KR930701989A (ko)	1993-09-08
RO114739B1 (ro)	1999-07-30
HU211617A9 (en)	1995-12-28
AU8731591A (en)	1992-05-20
SK36393A3 (en)	1993-07-07
CA2093206A1 (en)	1992-04-20
GB9022788D0 (en)	1990-12-05
HUT64215A (en)	1993-12-28
EP0553178A1 (en)	1993-08-04
CZ64193A3 (en)	1994-01-19
JP3276368B2 (ja)	2002-04-22

Publication	Publication Date	Title
FI104408B (sv)	2000-01-31	Förfarande för framställning av tvåfasiska avgivningsformulationer för lipofiliska läkemedel
US10668038B2 (en)	2020-06-02	Emulsion and emulsion preconcentrate compositions comprising omega-3 fatty acids and uses thereof are disclosed
Perlman et al.	2008	Development of a self-emulsifying formulation that reduces the food effect for torcetrapib
Rahman et al.	2013	Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS)
US20210059949A1 (en)	2021-03-04	Modified release composition comprising a cannabinoid
CN102470103B (zh)	2016-09-07	用作丙型肝炎病毒蛋白酶抑制剂的药物组合物
JP6116905B2 (ja)	2017-04-19	脂肪酸油混合物の被覆型カプセル剤および錠剤
JP6896019B2 (ja)	2021-06-30	脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
CA2982162C (en)	2023-10-10	Self-emulsifying formulations of dim-related indoles
JP6276756B2 (ja)	2018-02-07	１，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤
US20110033529A1 (en)	2011-02-10	Oral pharmaceutical paricalcitol formulations
CN106256345A (zh)	2016-12-28	维生素c传递系统及其脂质体组合物
WO2009069139A1 (en)	2009-06-04	Dosage form providing an ibuprofen-containing liquid fill
BRPI0008228B1 (pt)	2016-08-23	composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
WO2021163023A1 (en)	2021-08-19	Stable formulations of dronabinol
IL302169A (en)	2023-06-01	An oral cannabinoid formulation that includes medium chain triglycerides and tocopheryl phosphate
HRP980378A2 (en)	1999-04-30	Encapsulated solution dosage forms of sertraline
TW202128150A (zh)	2021-08-01	３＇—［（２ｚ）—［１—（３，４—二甲基苯基）—１，５—二氫—３—甲基—５—側氧基—４ｈ—吡唑—４—亞基］肼基］—２＇—羥基—［１，１＇—聯苯基］—３—甲酸及其鹽配製物
US20250064813A1 (en)	2025-02-27	Stable liquid pharmaceutical formulation
WO2012066347A1 (en)	2012-05-24	Oil based formulations
AU2922800A (en)	2000-09-21	Pharmaceutical compositions for oral administration comprising a benzamide and at least an absorption promoter
KR20100022626A (ko)	2010-03-03	나노입자 형성을 이용하는 리세드로네이트 경질캡슐